Last 16,150 KRW
Change Today +50.00 / 0.31%
Volume 68.7K
063160 On Other Exchanges
Symbol
Exchange
Korea SE
As of 2:07 AM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

ckd bio corp (063160) Snapshot

Open
16,100
Previous Close
16,100
Day High
16,750
Day Low
15,800
52 Week High
01/21/14 - 18,000
52 Week Low
06/5/14 - 12,200
Market Cap
84.5B
Average Volume 10 Days
22.5K
EPS TTM
194.00
Shares Outstanding
5.2M
EX-Date
12/27/13
P/E TM
83.2x
Dividend
100.00
Dividend Yield
0.62%
Current Stock Chart for CKD BIO CORP (063160)

Related News

No related news articles were found.

ckd bio corp (063160) Related Businessweek News

No Related Businessweek News Found

ckd bio corp (063160) Details

Ckd Bio Corporation manufactures, distributes, and imports and exports pharmaceuticals. Its offers products including Cephalosporins, penicillins, rifamycins, cyclosporine, demeclocycline hydrochloride, statins, clavulanate potassium and others. The company’s finished products include systemic anti-infectives, cardiovascular system, musculo-skeletal system, alimentary tract and metabolism, antineplastics and immunologicals, respiratory system, central nervous system, parasitology, blood and blood forming organs, systemic hormons, sensory organs, and diagnostic agents. Ckd Bio Corporation was founded in 1941 and is based in Seoul, South Korea.

Founded in 1941

ckd bio corp (063160) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ckd bio corp (063160) Key Developments

Ckd Bio Corporation, Annual General Meeting, Mar 21, 2014

Ckd Bio Corporation, Annual General Meeting, Mar 21, 2014., at 09:00 Korea Standard Time. Location: Gyeonggi-identity as Danwon 292. Agenda: To consider the audit reports, sales reports, external audit reports; to consider the financial statements - statement of retained earnings; to consider the cash dividend; to consider the election of director; to consider the appointment of audit; to consider the approval of directors' remuneration ceiling; to consider the approval of the audit fee ceiling; and to consider the incorporation of some changes.

Ckd Bio Corporation Announces Earnings Results for the Full Year Ended December 31, 2012

Ckd Bio Corporation announced earnings results for the full year ended December 31, 2012. For the year, total revenue was KRW 116,232.5 million against KRW 118,151.0 million a year ago. EBIT was KRW 11,270.4 million against KRW 15,806.9 million a year ago. Pre tax profit was KRW 8,118.6 million against KRW 12,981.7 million a year ago. Profit after tax was KRW 7,101.3 million against KRW 10,920.6 million a year ago. Return on equity was 5.7% against 9.2% a year ago. Return on assets was 3.8% against 5.5% a year ago. EPS was KRW 1,384.0 against KRW 2,129.0 per share a year ago.

Ckd Bio Corporation, Annual General Meeting, Mar 22, 2013

Ckd Bio Corporation, Annual General Meeting, Mar 22, 2013., at 10:00 Korea Standard Time. Location: Our factory (454), Danwon-Moknae-dong. Agenda: To approve the 12th financial Statement of Appropriation of Retained Earnings; to approve the appointment of director; to approve directors remuneration limit; to approve audit fees limit; to approve date of board resolution February 27, 2013; and to approve other references useful for making investment decisions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
063160:KS 16,150.00 KRW +50.00

063160 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 063160.
View Industry Companies
 

Industry Analysis

063160

Industry Average

Valuation 063160 Industry Range
Price/Earnings 86.2x
Price/Sales 0.8x
Price/Book 0.7x
Price/Cash Flow 87.9x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CKD BIO CORP, please visit www.ckdbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.